ZA953912B - Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein - Google Patents

Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein

Info

Publication number
ZA953912B
ZA953912B ZA953912A ZA953912A ZA953912B ZA 953912 B ZA953912 B ZA 953912B ZA 953912 A ZA953912 A ZA 953912A ZA 953912 A ZA953912 A ZA 953912A ZA 953912 B ZA953912 B ZA 953912B
Authority
ZA
South Africa
Prior art keywords
diagnostics
treatments
tyrosine phosphorylated
phosphorylated crkl
crkl protein
Prior art date
Application number
ZA953912A
Other languages
English (en)
Inventor
John H Groffen
Nora C Heisterkamp
Johanna Ten Hoeve
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Publication of ZA953912B publication Critical patent/ZA953912B/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA953912A 1994-05-13 1995-05-15 Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein ZA953912B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/242,513 US5667981A (en) 1994-05-13 1994-05-13 Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein

Publications (1)

Publication Number Publication Date
ZA953912B true ZA953912B (en) 1996-01-16

Family

ID=22915067

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA953912A ZA953912B (en) 1994-05-13 1995-05-15 Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein

Country Status (10)

Country Link
US (1) US5667981A (de)
EP (1) EP0759986B1 (de)
JP (1) JPH10503365A (de)
AT (1) ATE175996T1 (de)
AU (1) AU691927B2 (de)
CA (1) CA2190161A1 (de)
DE (1) DE69507470D1 (de)
IL (1) IL113720A0 (de)
WO (1) WO1995031545A2 (de)
ZA (1) ZA953912B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
DK0983510T3 (da) * 1997-05-20 2004-07-05 Univ Erasmus Genkendelse af tumorspecifikke genprodukter i cancer
US6686165B2 (en) 1997-05-20 2004-02-03 Erasmus Universiteit Rotterdam Recognition of tumor-specific gene products in cancer
WO1999067380A1 (en) * 1998-06-22 1999-12-29 Temple University - Of The Commonwealth System Of Higher Education c-Cbl SUPPRESSION OF NEOPLASTIC TRANSFORMATION
US20050230315A1 (en) * 2003-01-13 2005-10-20 Regents Of The University Of Michigan Protein microarray system
US20080280771A1 (en) * 2000-02-08 2008-11-13 Regents Of The University Of Michigan Protein MicroarraySystem
DE60026732T2 (de) * 2000-03-23 2006-08-17 Japan Science And Technology Agency, Kawaguchi Zellenreihen-extraktionsverfahren
WO2003023380A1 (en) 2001-09-10 2003-03-20 Meso Scale Technologies, Llc Assay buffer, compositions containing the same, and methods of using the same
ATE443259T1 (de) 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
US20030190688A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology, Inc. Methods for detecting BCR-ABL signaling activity in tissues using phospho-specific antibodies
WO2004053074A2 (en) * 2002-12-06 2004-06-24 Science And Technology Corporation @ Unm Outcome prediction and risk classification in childhood leukemia
JP4602772B2 (ja) * 2002-12-27 2010-12-22 中外製薬株式会社 Ｗｔ１遺伝子トランスジェニック動物
US20070219117A1 (en) * 2003-10-27 2007-09-20 Medvet Science Pty Ltd Bidentate motif and methods of use
EP2126580A4 (de) * 2005-02-10 2010-11-10 Cell Signaling Technology Inc Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
US20110189095A1 (en) * 2008-06-20 2011-08-04 The Board Of Regents, Of The University Of Texas System Crkl targeting peptides
WO2012030738A2 (en) * 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
US9637523B2 (en) 2012-08-31 2017-05-02 Westfaelische Wilhelms-Universitaet Muenster Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
JP7300642B2 (ja) * 2019-06-14 2023-06-30 国立大学法人浜松医科大学 特発性肺線維症の予後予測方法
CN115991789B (zh) * 2022-07-14 2024-06-04 华中科技大学 一种基于sh2超亲体的融合蛋白及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH082799B2 (ja) * 1987-03-06 1996-01-17 秀雄 麦島 骨髄線維症治療剤
WO1993003377A1 (en) * 1991-07-31 1993-02-18 Ziltener Hermann J Method for the detection of phosphotyrosine residues
CA2054602C (en) * 1991-10-31 2003-04-22 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system

Also Published As

Publication number Publication date
DE69507470D1 (de) 1999-03-04
CA2190161A1 (en) 1995-11-23
ATE175996T1 (de) 1999-02-15
AU691927B2 (en) 1998-05-28
JPH10503365A (ja) 1998-03-31
IL113720A0 (en) 1995-10-31
EP0759986B1 (de) 1999-01-20
AU2689095A (en) 1995-12-05
WO1995031545A3 (en) 1996-08-01
EP0759986A1 (de) 1997-03-05
US5667981A (en) 1997-09-16
WO1995031545A2 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
ZA953912B (en) Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
MX9708401A (es) Genes reguladores de la cromatina.
ES2159318T3 (es) Inhibidores de la proteina quinasa c.
NO970039D0 (no) Fremgangsmåte for inhibering av cancer matastaser ved oral administrering av opplöselig modifisert sitruspektin
ATE408422T1 (de) Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
WO1998035693A3 (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
GB9411671D0 (en) Tumor diagnosis and prognosis
WO1999058692A3 (en) Human apoptosis associated proteins
AU2385095A (en) Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
EP1163515A4 (de) Therapeutische und diagnostische mittel für krankheiter mit gestörter glukose-tolerenz
AU3392901A (en) Proteins
WO1999028461A3 (en) Methods and means for inducing apoptosis by interfering with bip-like proteins
ATE180974T1 (de) Zusammensetzungen und methoden zur behandlung von kleinzell und nicht-kleinzell lungenkrebsen
HK1011560A1 (en) Method of diagnosing and treating epithelioma
AU2932100A (en) Neurodegenerative disorder related gene
EP1019092A4 (de) Therapeutische und diagnostische mittel für krankheiten mit gestörter glukose-toleranz
ATE316136T1 (de) Nierenpolycystose-gen
IL189502A0 (en) Methods and compositions for inhibiting neoplastic cell growth
ATE363916T1 (de) Die expression von cyclin g1 in tumoren
GB9800378D0 (en) Proteome analysis
AU2240597A (en) Cardiovascular and thrombus imaging agents, methods and kits
EP0846263A4 (de) Verfahren und testsatz zur evaluierung der metastaseneigung von tumoren
AU4654097A (en) Rdgb-proteins
WO2003029482A3 (en) Diagnosing, treating, and preventing cancer using cables
WO2000000510A1 (en) MODULATORS OF THE GROWTH FACTOR